Scientific Program
Scientific Program	Search Abstract
Session
Chronic myeloid leukemia - Biology & Clinical
Date:	Saturday, 06 June 2009
Time:	18:00-19:15
Room:
18:00-19:15
NILOTINIB SIGNIFICANTLY INDUCES APOPTOSIS IN IMATINIB RESISTANT K562 CELLS, AS EFFECTIVELY AS IN PARENTAL SENSITIVE COUNTERPARTS		0851
BARAN, YUSUF, CAN, GEYLANI, EKIZ, HUSEYIN ATAKAN (IZMIR, Turkey)
18:00-19:15
LACK OF KRAS MUTATIONS IN BCR-ABL MUTATION NEGATIVE CML PATIENTS RESISTANT TO FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS		0852
Erben, Philipp, Agrawal, Mridul, Mueller, Martin Christian, Schenk, Thomas, Daikeler, Hannah, Hofheinz, Ralf Dieter, Hehlmann, Ruediger, Reiter, Andreas, Hochhaus, Andreas (Mannheim, Germany)
18:00-19:15
ACQUIRED IMATINIB RESISTANCE IN CML IS ASSOCIATED WITH TKD MUTATIONS OF BCR-ABL AND/OR ADDITIONAL CHROMOSOMAL ABERRATIONS: CERTAIN TKD MUTATIONS ARE ASSOCIATED WITH CHROMOSOME INSTABILITY		0853
Dicker, Frank, Kern, Wolfgang, Haferlach, Torsten, Haferlach, Claudia, Schnittger, Susanne (Munich, Germany)
18:00-19:15
ROLE OF ABC TRANSPORTERS IN THE DEVELOPMENT OF IMATINIB RESISTANCE		0854
Gromicho, Marta, Dinis, Joana, Martins, Célia, Laires, António, Rueff, José, Rodrigues, António (Lisbon, Portugal)
18:00-19:15
EIGHTEEN YEARS EXPERIENCE WITH AUTOGRAFTING FOLLOWED BY IFN-A AND IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). THE GENOA EXPERIENCE		0855
Carella, Angelo Michele, Beltrami, Germana, Garuti, Anna, Catania, Gioacchino, Pica, Gianmatteo, Biasco, Samantha, Nati, Sandro, Congiu, Angela, Vimercati, Renato, Rossi, Edoardo, Spriano, Mauro (Genova, Italy)
18:00-19:15
COMPARISON OF HIGH PREFORMANCE LIQUID CHROMATOGRAPHY-ULTRAVIOLET DETECTION (HPLC-UV) VS LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY (LC/MS/MS) TO DETERMINE IMATINIB PLASMA LEVELS IN CML-CP PATIENTS		0856
Awidi, Abdalla, Salem, Isam, Najib, Naji, Mefleh, Razan, Tarawneh, Bothainah (Amman, Jordan)
18:00-19:15
NO INHIBITION OF WARFARIN PHARMACOKINETICS AND PHARMACODYNAMICS BY NILOTINIB IN HUMAN SUBJECTS		0857
Yin, Ophelia, Gallagher, Neil, Fischer, Deirdre, Zhao, Lily, Zhou, Wei, Golor, Georg, Schran, Horst (Florham Park, United States of America)
18:00-19:15
EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE		0858
Zackova, Daniela, Klamova, Hana, Doubek, Michael, Pospisil, Zdenek, Dvorakova, Dana, Jurcek, Tomas, Moravcova, Jana, Machova, Katerina, Rulcova, Jana, Dobesova, Blanka, Rysava, Jana, Cetkovsky, Petr, Razga, Filip, Mayer, Jiri (Brno, Czech Republic)
18:00-19:15
CHRONIC MYELOID LEUKAEMIA PATIENTS WITH THE E13A2 BCR-ABL TRANSCRIPT HAVE INFERIOR RESPONSE TO IMATINIB THAN E14A2 PATIENTS		0859
Lucas, Claire, Harris, Robert, Wang, Lihui, Knight, Katy, Watmough, Sarah, Clark, Richard (Liverpool, United Kingdom)
18:00-19:15
OVERVIEW OF CHRONIC MYELOID LEUKEMIA AND CURRENT DIAGNOSIS AND TREATMENT PATTERNS FROM 15 HOSPITALS IN CHINA		0860
Wang, Jianxiang , Wang, Ying (P), Qiu, Lugui, Huang, Xiaojun, Jiang, Bin, Wu, Depei, Sun, Aining, Hu, Jianda, Liu, Tingbo, Liu, Ting, Zhu, Huanling, Hu, Yu, Guo, Tao, Meng, Fanyi, Xv, Dan, Chen, Xiequn, Hou, Ming, Ji, Chunyan, Li, Yan, Lv, Xiaoyi, Wang, Shujie, Jiao, Li, Wang, Jianmin, Ren, Hanyun, Yu, Li, Chen, Fangyuan (TIANJIN , China)
18:00-19:15
CHRONIC MYELOID LEUKEMIA AS SECOND MALIGNANCY; A RETROSPECTIVE MULTICENTRIC STUDY		0861
Iannitto, Emilio, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raimondo, F, Ferrara, F, Franco, G, Liardo, E, Mancuso, S, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo-Rossi, A, Specchia, G, Turri, D, Abbadessa, V (Palermo, Italy)
18:00-19:15
LONG-TERM FOLLOW-UP AND SAFETY OF DASATINIB IN CML/ALL PH1 IMATINIB RESISTANT PATIENTS IN A COMPASSIONATE USE PROGRAM		0862
Gozzini, Antonella, Stagno, Fabio, Rege Cambrin, Giovanna, Luciano, Luigia, Breccia, Massimo, Abruzzese, Elisabetta, Martinelli, Giovanni, Orlandi, Ester, Gobbi, Marco, Pregno, Patrizia, Sica, Simona, Pungolino, Ester, Angelucci, Emanuele, Musso, Maurizio, Bruno, Martino, Galimberti, Sara, Nieddu, Rosa, Specchia, Giorgina, Kropp, Maria Grazia, Annunziata, Mario, Musto, Pellegrino, Cervellera, Martino, Carella, Angelo Michele, Pini, Massimo, Radaelli, Franca, Meneghini, Vittorio, Russo, Domenico, Montefusco, Enrico, Marasca, Roberto, Gaidano, Gianluca, Cavazzini, Francesco, Ciccone, Fabrizio (Firenze, Italy)
18:00-19:15
EFFECT OF THE PROTON PUMP INHIBITOR ESOMEPRAZOLE ON THE ORAL ABSORPTION AND PHARMACOKINETICS OF NILOTINIB		0863
Yin, Ophelia, Gallagher, Neil, Fischer, Deirdre, Demirhan, Eren, Zhou, Wei, Golor, Georg, Schran, Horst (Florham Park, United States of America)
18:00-19:15
IMATINIB TREATMENT IN ELDERLY PATIENTS (>65 YEARS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE		0864
Latagliata, Roberto, Breccia, Massimo, Carmosino, Ida, Mancini, Marco, Diverio, Daniela, De Cuia, Rosa, Cannella, Laura, Stefanizzi, Caterina, Napoleone, Laura, Volpicelli, Paola, Vozella, Federico, Alimena, Giuliana (Rome, Italy)
18:00-19:15
EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR –INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): FINAL SAFETY ANALYSIS OF 117 CHINESE CML PATIENTS		0865
Shen, Zhixiang, Huang, Xiaojun, Meng, Fanyi, Wang, Jianxiang, Liu, Ting, Hu, Jianda, Wang, Jim, Zhao, Yan, Woodman, Richard, Zou, Ping (Shanghai, China)
18:00-19:15
PROANGIOGENIC CYTOKINES IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB MESYLATE		0866
Kotlyarchuk, Kostyantyn, Lukavetsky, Les, Danysh, Olga, Lukjanova, Anna, Kolisnyk, Maryana, Maslyak, Zvenyslava (Lviv, Ukraine)
18:00-19:15
IMATINIB DOSE ESCALATION FOR CML RESISTANT PATIENTS IS USEFUL IN GENERAL PRACTICE: IMPACT ON CYTOGENETIC REMISSION		0867
Zaritskey, Andrey (StPetersburg, Russian Federation)